跳至主要内容
临床试验/NCT07707804
NCT07707804尚未招募不适用

Study on The Impact of Bionic Balloon-assisted Delivery Technology on the Labor Process and Maternal and Neonatal Outcomes

Peking Union Medical College Hospital4 个研究点 分布在 1 个国家目标入组 300 人开始时间: 2026年7月15日最近更新:
适应症

试验速览

阶段
不适用
状态
尚未招募
入组人数
300
试验地点
4
主要终点
Duration of Labor

研究概览

简要总结

This multicenter, prospective, randomized controlled trial will evaluate the efficacy and safety of bionic balloon-assisted delivery technology in nulliparous women planning vaginal delivery. Eligible participants will be randomly assigned in a 1:1 ratio to either the intervention group or the control group. Participants in the control group will receive routine labor management, while participants in the intervention group will receive bionic balloon-assisted delivery in addition to routine labor management after entering the active phase of labor.

The primary outcome is the duration of labor, including the first, second, and third stages of labor. Secondary outcomes include intrapartum cesarean conversion rate, intrapartum and postpartum complications, neonatal outcomes, postpartum pelvic floor dysfunction, postpartum depression, and maternal satisfaction. This study aims to determine whether bionic balloon-assisted delivery can shorten labor duration, reduce intrapartum cesarean conversion, and improve maternal and neonatal outcomes without increasing adverse events.

详细描述

Bionic balloon-assisted delivery is a physical delivery-assistance technique designed to simulate the pressure and stimulation exerted by the fetal presenting part on the cervix and birth canal during labor. By providing controlled mechanical dilation of the upper and lower vagina during the active phase of labor, this technique may promote labor progress without the use of additional pharmacologic agents.

This study is a multicenter, prospective, randomized controlled trial designed to evaluate the efficacy and safety of bionic balloon-assisted delivery technology in nulliparous women planning vaginal delivery. Eligible participants will be women aged 18 to 45 years with singleton, term pregnancy, cephalic presentation, no contraindications to vaginal delivery, latent phase longer than 3 hours, cervical dilation greater than 4 to 5 centimeters indicating entry into the active phase of labor, fetal head engagement, and no obvious cephalopelvic disproportion. After written informed consent is obtained, participants will be randomly assigned in a 1:1 ratio to either the intervention group or the control group.

Participants in the control group will receive routine labor management for vaginal delivery. This includes close monitoring after the onset of labor, artificial rupture of membranes when cervical dilation reaches more than 4 to 5 centimeters and the fetal head is engaged, continued observation of uterine contractions, fetal heart rate, and amniotic fluid characteristics, and operative vaginal delivery or emergency cesarean section when clinically indicated.

Participants in the intervention group will receive bionic balloon-assisted delivery in addition to routine labor management. After the participant enters the active phase of labor and the fetal head is engaged, the KCB-II automatic bionic balloon-assisted delivery device will be used with a sterile latex balloon dilation handle. The balloon will be placed in the upper vagina near the fornix after artificial rupture of membranes and inflated according to the study protocol to mechanically dilate the birth canal. Other labor management procedures will follow routine clinical practice.

The primary outcome is the duration of labor, including the first, second, and third stages of labor. Secondary outcomes include intrapartum cesarean conversion rate; intrapartum and postpartum complications such as intrapartum fever, postpartum hemorrhage, postpartum infection, urinary retention, soft birth canal laceration, episiotomy, and operative vaginal delivery; neonatal outcomes including birth weight, Apgar scores, umbilical artery blood gas analysis results when available, neonatal complications, and admission to the neonatal intensive care unit; postpartum pelvic floor dysfunction; postpartum depression assessed using the Edinburgh Postnatal Depression Scale; and maternal satisfaction.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

盲法说明

If there are other parties who are masked in the clinical trial besides those listed above, use this space to describe those parties.

入排标准

年龄范围
18 Years 至 45 Years(Adult)
性别
Female
接受健康志愿者

入选标准

  • Age: 18-45 years;
  • Nulliparous women with singleton, term pregnancy, cephalic presentation, and no contraindications to vaginal delivery;
  • Latent phase longer than 3 hours, cervical dilation greater than 4-5 cm (entry into the active phase), fetal head engagement, and no obvious cephalopelvic disproportion;
  • Voluntary participation in this study and signing of written informed consent.

排除标准

  • Multiparous women;
  • Non-cephalic presentation;
  • Genital tract infection;
  • High-risk pregnancy score classified as "red ball," "purple ball," or some "orange ball" categories, including severe medical or surgical comorbidities, placenta previa, scarred uterus, etc.;
  • Presence of cephalopelvic disproportion, abnormal fetal heart rate, or other conditions unsuitable for vaginal delivery and requiring cesarean section;
  • Other conditions considered unsuitable for enrollment by the clinician.

结局指标

主要结局

Duration of Labor

时间窗: From onset of labor to delivery of the placenta.

The duration of labor will be measured, including the first, second, and third stages of labor. The first stage of labor is defined as the period from the onset of labor to full cervical dilation; the second stage is defined as the period from full cervical dilation to delivery of the fetus; and the third stage is defined as the period from delivery of the fetus to delivery of the placenta.

次要结局

  • Incidence of Urinary Retention(From onset of labor to 48 hours after delivery)
  • Intrapartum Cesarean Conversion Rate(During labor and delivery)
  • Incidence of Intrapartum Fever(From onset of labor to delivery)
  • Incidence of Postpartum Hemorrhage(Within 24 hours after delivery)
  • Incidence of Postpartum Infection(From 24 hours to 48 hours after delivery)
  • Incidence of Soft Birth Canal Laceration(At delivery)
  • Incidence of Episiotomy(At delivery)
  • Incidence of Operative Vaginal Delivery(At delivery)
  • Neonatal Birth Weight(At birth)
  • Apgar Score at 1 Minute(1 minute after birth)
  • Apgar Score at 5 Minutes(5 minutes after birth)
  • Apgar Score at 10 Minutes(10 minutes after birth)
  • Umbilical Artery Blood pH(At birth)
  • Admission to the Neonatal Intensive Care Unit(From birth to 48 hours after birth)
  • Incidence of Neonatal Infection(From birth to 48 hours after birth)
  • Incidence of Meconium Aspiration(From birth to 48 hours after birth)
  • Incidence of Neonatal Hypoxia(From birth to 48 hours after birth)
  • Incidence of Perinatal Death(From birth to 7 days after birth)
  • Maternal Satisfaction(2-3 days postpartum before discharge)
  • Incidence of Postpartum Pelvic Floor Dysfunction(42 days postpartum)
  • Incidence of Postpartum Depression(42 days postpartum)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Yifeng Zhong

Associate Professor

Peking Union Medical College Hospital

研究点 (4)

Loading locations...

相似试验

Bionic Balloon-assisted Delivery Technology on the... | 临床试验